Fintel reports that on January 13, 2025, Needham downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) from ...

Fintel reports that on January 14, 2025, Piper Sandler downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...

Explore the role of preclinical MRI in studying neurological diseases, with a focus on advanced cellular and molecular ...

Intra-Cellular Therapies Inc (ITCI) stock saw a decline, ending the day at $126.2 which represents a decrease of $-0.06 or -0.05% from the prior close of $126.26. The stock opened at $126.65 and ...

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...

As the first and most advanced cellular therapy centre in the UAE, the UC-MSCs used for this therapy were fully produced at ADSCC’s advanced laboratories ...

The deal would help accelerate growth in J&J's drugs business after the company spun off its consumer health unit in 2023.

"Berries offer an exceptional combination of nutrients and compounds that support longevity and healthy aging. They’re ...